A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
← catalyst calendarNCT06360354 · readout in 73 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
120actual
Sites
77
Countries
Australia, Belgium, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-29 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Interventions
- Drug: Anvumetostat — also filed as AMG 193
- Drug: Gemcitabine
- Drug: Nab-paclitaxel
- Drug: Modified FOLFIRINOX
- Drug: RMC-6236
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Dose Limiting Toxicities (DLT)
measured Up to 28 days
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)
measured Up to approximately 2 years
Number of Participants Experiencing Serious Adverse Events (SAE)
measured Up to approximately 2 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed